In an article published on January 11, 2018 in the peer-reviewed journal Food and Chemical Toxicology, Shruti Kabadi and colleagues from the U.S. Food and Drug Administration (FDA) evaluated the human biopersistence potential of shorter-chain polyfluorinated compounds (PFCs). PFCs are authorized and commonly used as grease-proofing agents in food contact paper. Longer-chain C8-PFCs have been replaced with the shorter-chain C6-PFCs due to the concerns over the C8-PFCs’ potential to accumulate in human tissues. However, the bioaccumulation potential of the C6-PFCs themselves has not been fully evaluated up to now.
The scientists estimated the internal exposure to several key metabolites of 6:2 fluorotelomer alcohol (6:2 FTOH), which is a monomeric component of C6-PFCs. Their study demonstrated the high biopersistence potential of 6:2 FTOH, and identified one of its metabolites, 5:3 fluorotelomer carboxylic acid (5:3 A), as an important biomarker. It can be used in biomonitoring studies or for assessment of chronic exposure to 6:2 FTOH through diet.
In an article published on January 18, 2018 by regulatory news provider Chemical Watch, reporter Emma Davies pointed out that 6:2 FTOH is also a metabolite of 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoroctyl methacrylate (FTMA, CAS 2144-53-8). This chemical is currently being evaluated by Germany under the Community Rolling Action Plan (CoRAP) as several in vitro studies have suggested that 6:2 FTOH may have estrogenic activity.
Emma Davies (January 18, 2018). “FDA scientists voice concerns over metabolites of food contact substance.” Chemical Watch
Kabadi, S., et al. (2018). “Internal exposure-based pharmacokinetic evaluation of potential for biopersistence of 6:2 fluorotelomer alcohol (FTOH) and its metabolites.” Food and Chemical Toxicology (published January 11, 2018).